TABLE 2

Identification and characterization of reported and tentative products of paclitaxel metabolism

Profiles
Rats
Humans
Known products di-OHP C3′-OHP C3′-OHP 6α-OHP Paclitaxel
Tentative products C2-OHP OHP C2-OHP
Authentic standard n.a. Yes n.a. n.a. Yes n.a. Yes Yes
% tR of paclitaxela 41 ± 0.15 51.7 ± 0.2 62.8 ± 0.3 80.4 ± 0.15 51.7 ± 0.2 62.8 ± 0.3 79.55 ± 0.15 100
tR for HPLC-UVa (min) 6.15 7.76 9.42 12.06 7.76 9.42 12.06 15
tR for HPLC-MSa (min) 3.16 3.92 4.73 5.56 3.92 4.73 6.12 6.52
MH + HPLC-MSa 886.3 870.3 870.3 870.3 870.3 870.3 870.3 854.3
HPLC-MS di-OHP C3′-OHP OHP OHP C3′-OHP OHP 6α-OHP Paclitaxel
Order of amount, literatureb n.r. 1 2 n.r. 2 1 n.r.
Order of amount, our data 4 1 2 3 2 3 1
Inference
di-OHP
C3′-OHP
C2-OHP
OHP
C3′-OHP
C2-OHP
6α-OHP
Paclitaxel

  • n.a., not available; n.r., has not been reported before.

  • ↵ a Our data

  • ↵ b HPLC conditions for detection: rat microsomes, [3H]Taxol HPLC separation, mobile phase 35% acetonitrile, wavelength 229 nm, flow rate 1 ml/min (Walle et al., 1993; Anderson et al., 1995); human microsomes, mobile phase 35% acetonitrile, wavelength 229 nm, flow rate 0.6 ml/min (Kumar et al., 1994), mobile phase methanol/H2O (65:35), 235 nm, flow rate 1 ml/min (Cresteil et al., 1994)